PetVivo Reports Q3 Fiscal 2026 Financial Results and Strategic Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Source: Newsfilter
- Strategic Licensing Agreement: PetVivo signed a 10-year exclusive white-label licensing agreement with Digital Landia for its AgenticPet AI technology, which aims to address skyrocketing client acquisition costs in the veterinary industry, potentially enhancing the company's competitive edge in the rapidly growing pet market.
- Customer Acquisition Cost Reduction: The newly launched PetVivo.ai platform demonstrated a reduction in customer acquisition costs from $80-$400 per target customer to under $43 during beta testing, which is expected to generate high gross margins of 80%-90% and create a new recurring revenue stream for the company.
- International Market Expansion: PetVivo's collaboration with Nupsala Group introduces its Spryng product to the UK market, with initial orders shipped, which is anticipated to further drive the company's market penetration in Europe to meet the growing demand from veterinarians.
- Regulatory Recognition: Health Canada has officially recognized Spryng as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy, with plans to launch in Canada in Q3 2026, opening up new market opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
